Literature DB >> 25139440

Novel paracrine modulation of Notch-DLL4 signaling by fibulin-3 promotes angiogenesis in high-grade gliomas.

Mohan S Nandhu1, Bin Hu2, Susan E Cole3, Anat Erdreich-Epstein4, Diego J Rodriguez-Gil5, Mariano S Viapiano1.   

Abstract

High-grade gliomas are characterized by exuberant vascularization, diffuse invasion, and significant chemoresistance, resulting in a recurrent phenotype that makes them impossible to eradicate in the long term. Targeting protumoral signals in the glioma microenvironment could have significant impact against tumor cells and the supporting niche that facilitates their growth. Fibulin-3 is a protein secreted by glioma cells, but absent in normal brain, that promotes tumor invasion and survival. We show here that fibulin-3 is a paracrine activator of Notch signaling in endothelial cells and promotes glioma angiogenesis. Fibulin-3 overexpression increased tumor VEGF levels, microvascular density, and vessel permeability, whereas fibulin-3 knockdown reduced vessel density in xenograft models of glioma. Fibulin-3 localization in human glioblastomas showed dense fiber-like condensations around tumor blood vessels, which were absent in normal brain, suggesting a remarkable association of this protein with tumor endothelium. At the cellular level, fibulin-3 enhanced endothelial cell motility and association to glioma cells, reduced endothelial cell sprouting, and increased formation of endothelial tubules in a VEGF-independent and Notch-dependent manner. Fibulin-3 increased ADAM10/17 activity in endothelial cells by inhibiting the metalloprotease inhibitor TIMP3; this resulted in increased Notch cleavage and increased expression of DLL4 independently of VEGF signaling. Inhibition of ADAM10/17 or knockdown of DLL4 reduced the proangiogenic effects of fibulin-3 in culture. Taken together, these results reveal a novel, proangiogenic role of fibulin-3 in gliomas, highlighting the relevance of this protein as an important molecular target in the tumor microenvironment. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25139440      PMCID: PMC4184948          DOI: 10.1158/0008-5472.CAN-14-0685

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization.

Authors:  Naoyuki Kobayashi; Günter Kostka; Jörg H O Garbe; Douglas R Keene; Hans Peter Bächinger; Franz-Georg Hanisch; Dessislava Markova; Takeshi Tsuda; Rupert Timpl; Mon-Li Chu; Takako Sasaki
Journal:  J Biol Chem       Date:  2007-02-26       Impact factor: 5.157

Review 2.  Fibulins and cancer: friend or foe?

Authors:  William M Gallagher; Caroline A Currid; Linda C Whelan
Journal:  Trends Mol Med       Date:  2005-07       Impact factor: 11.951

3.  Fibrillin-1 interactions with fibulins depend on the first hybrid domain and provide an adaptor function to tropoelastin.

Authors:  Ehab El-Hallous; Takako Sasaki; Dirk Hubmacher; Melkamu Getie; Kerstin Tiedemann; Jürgen Brinckmann; Boris Bätge; Elaine C Davis; Dieter P Reinhardt
Journal:  J Biol Chem       Date:  2007-01-25       Impact factor: 5.157

4.  Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma.

Authors:  E W L Law; A K L Cheung; V I Kashuba; T V Pavlova; E R Zabarovsky; H L Lung; Y Cheng; D Chua; D Lai-Wan Kwong; S W Tsao; T Sasaki; E J Stanbridge; M L Lung
Journal:  Oncogene       Date:  2011-07-11       Impact factor: 9.867

5.  Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4.

Authors:  R Giltay; R Timpl; G Kostka
Journal:  Matrix Biol       Date:  1999-10       Impact factor: 11.583

6.  Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion.

Authors:  Jeffrey S Scehnet; Weidong Jiang; S Ram Kumar; Valery Krasnoperov; Alexandre Trindade; Rui Benedito; Dusan Djokovic; Cristina Borges; Eric J Ley; Antonio Duarte; Parkash S Gill
Journal:  Blood       Date:  2007-02-20       Impact factor: 22.113

Review 7.  Association of EFEMP1 with malattia leventinese and age-related macular degeneration: a mini-review.

Authors:  Lihua Marmorstein
Journal:  Ophthalmic Genet       Date:  2004-09       Impact factor: 1.803

8.  A regulatory network involving Foxn4, Mash1 and delta-like 4/Notch1 generates V2a and V2b spinal interneurons from a common progenitor pool.

Authors:  Marta G Del Barrio; Raquel Taveira-Marques; Yuko Muroyama; Dong-In Yuk; Shengguo Li; Mary Wines-Samuelson; Jie Shen; Hazel K Smith; Mengqing Xiang; David Rowitch; William D Richardson
Journal:  Development       Date:  2007-08-29       Impact factor: 6.868

9.  Fibulins 3 and 5 antagonize tumor angiogenesis in vivo.

Authors:  Allan R Albig; Jason R Neil; William P Schiemann
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  19 in total

1.  Fibulin-3 promotes muscle-invasive bladder cancer.

Authors:  A L Han; B A Veeneman; L El-Sawy; K C Day; M L Day; S A Tomlins; E T Keller
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

2.  Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.

Authors:  Mohan S Nandhu; Prajna Behera; Vivek Bhaskaran; Sharon L Longo; Lina M Barrera-Arenas; Sadhak Sengupta; Diego J Rodriguez-Gil; E Antonio Chiocca; Mariano S Viapiano
Journal:  Clin Cancer Res       Date:  2017-11-16       Impact factor: 12.531

3.  VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme.

Authors:  Aleksandra Gruslova; David A Cavazos; Jessica R Miller; Eyal Breitbart; Yael C Cohen; Livnat Bangio; Niva Yakov; Anu Soundararajan; John R Floyd; Andrew J Brenner
Journal:  J Neurooncol       Date:  2015-06-25       Impact factor: 4.130

4.  BCL3 expression promotes resistance to alkylating chemotherapy in gliomas.

Authors:  Longtao Wu; Giovanna M Bernal; Kirk E Cahill; Peter Pytel; Carrie A Fitzpatrick; Heather Mashek; Ralph R Weichselbaum; Bakhtiar Yamini
Journal:  Sci Transl Med       Date:  2018-07-04       Impact factor: 17.956

Review 5.  Notch signaling in malignant gliomas: supporting tumor growth and the vascular environment.

Authors:  Franciele C Kipper; Mark W Kieran; Ajith Thomas; Dipak Panigrahy
Journal:  Cancer Metastasis Rev       Date:  2022-05-27       Impact factor: 9.237

6.  Fibulin-3 Deficiency Protects Against Myocardial Injury Following Ischaemia/ Reperfusion in in vitro Cardiac Spheroids.

Authors:  Poonam Sharma; Dominik Beck; Lucy A Murtha; Gemma Figtree; Andrew Boyle; Carmine Gentile
Journal:  Front Cardiovasc Med       Date:  2022-06-20

7.  Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours.

Authors:  Hengkang Yan; Mary E Vail; Linda Hii; Nancy Guo; Paul J McMurrick; Karen Oliva; Simon Wilkins; Nayanendu Saha; Dimitar B Nikolov; Fook-Thean Lee; Andrew M Scott; Peter W Janes
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 8.  Notch: A multi-functional integrating system of microenvironmental signals.

Authors:  Bryce LaFoya; Jordan A Munroe; Masum M Mia; Michael A Detweiler; Jacob J Crow; Travis Wood; Steven Roth; Bikram Sharma; Allan R Albig
Journal:  Dev Biol       Date:  2016-08-24       Impact factor: 3.582

Review 9.  Radioimmunotherapy (RIT) in Brain Tumors.

Authors:  Ali Gholamrezanezhad; Hossein Shooli; Narges Jokar; Reza Nemati; Majid Assadi
Journal:  Nucl Med Mol Imaging       Date:  2019-11-12

10.  Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis.

Authors:  Henriette Merk; Siwei Zhang; Thorsten Lehr; Christoph Müller; Melanie Ulrich; James A Bibb; Ralf H Adams; Franz Bracher; Stefan Zahler; Angelika M Vollmar; Johanna Liebl
Journal:  Oncotarget       Date:  2016-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.